Ipsen Acquires ImCheck Therapeutics to Strengthen Oncology Portfolio

In a recent announcement, Ipsen revealed plans to acquire ImCheck Therapeutics, expanding its oncology leadership. The acquisition is centered on ImCheck's lead program, ICT01, a monoclonal antibody targeting acute myeloid leukemia (AML), which has shown promising results in early clinical trials. The drug aims to address the unmet needs of AML patients ineligible for intensive chemotherapy, potentially setting a new standard of care.

ImCheck's shareholders will receive 350 million euros upfront, with potential payments up to 1 billion euros based on milestone achievements. The deal is anticipated to finalize in early 2026, subject to regulatory approvals. This acquisition underscores Ipsen’s commitment to advancing transformative cancer therapies and capitalizes on ImCheck's innovative immuno-oncology research.